These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31173909)

  • 1. The safety evaluation of long-acting ocular delivery systems.
    Thackaberry EA; Lorget F; Farman C; Bantseev V
    Drug Discov Today; 2019 Aug; 24(8):1539-1550. PubMed ID: 31173909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein conjugates and fusion proteins as ocular therapeutics.
    Mehta SC; Kelley RF; Tesar DB
    Drug Discov Today; 2019 Aug; 24(8):1440-1445. PubMed ID: 31202674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in intraocular sustained-release drug delivery devices.
    Cao Y; Samy KE; Bernards DA; Desai TA
    Drug Discov Today; 2019 Aug; 24(8):1694-1700. PubMed ID: 31173915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled and continuous release ocular drug delivery systems: pros and cons.
    Abdelkader H; Alany RG
    Curr Drug Deliv; 2012 Jul; 9(4):421-30. PubMed ID: 22640036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo evaluation of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and beyond.
    Destruel PL; Zeng N; Maury M; Mignet N; Boudy V
    Drug Discov Today; 2017 Apr; 22(4):638-651. PubMed ID: 28017837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advance of the application of nano-controlled release system in ophthalmic drug delivery.
    Wang X; Wang S; Zhang Y
    Drug Deliv; 2016 Oct; 23(8):2897-2901. PubMed ID: 26635087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular biopharmaceutics: impact of modeling and simulation on topical ophthalmic formulation development.
    Gukasyan HJ; Hailu S; Karami TK; Graham R
    Drug Discov Today; 2019 Aug; 24(8):1587-1597. PubMed ID: 30959112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and opportunities for drug delivery to the posterior of the eye.
    Cabrera FJ; Wang DC; Reddy K; Acharya G; Shin CS
    Drug Discov Today; 2019 Aug; 24(8):1679-1684. PubMed ID: 31175955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in ocular drug delivery.
    Achouri D; Alhanout K; Piccerelle P; Andrieu V
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug delivery to the posterior segment of the eye.
    Fischer N; Narayanan R; Loewenstein A; Kuppermann BD
    Eur J Ophthalmol; 2011; 21 Suppl 6():S20-6. PubMed ID: 23264325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug delivery systems and novel formulations to improve treatment of rare corneal disease.
    Jimenez J; Sakthivel M; Nischal KK; Fedorchak MV
    Drug Discov Today; 2019 Aug; 24(8):1564-1574. PubMed ID: 30872110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery.
    Shen HH; Chan EC; Lee JH; Bee YS; Lin TW; Dusting GJ; Liu GS
    Nanomedicine (Lond); 2015; 10(13):2093-107. PubMed ID: 26096379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic implications of nanomedicine for ocular drug delivery.
    Meng T; Kulkarni V; Simmers R; Brar V; Xu Q
    Drug Discov Today; 2019 Aug; 24(8):1524-1538. PubMed ID: 31102733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In situ gel systems as 'smart' carriers for sustained ocular drug delivery.
    Agrawal AK; Das M; Jain S
    Expert Opin Drug Deliv; 2012 Apr; 9(4):383-402. PubMed ID: 22432690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations.
    Shen J; Lu GW; Hughes P
    Pharm Res; 2018 Sep; 35(11):217. PubMed ID: 30255364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular drug delivery-eye on innovation.
    Rupenthal ID; O'Rourke M
    Drug Deliv Transl Res; 2016 Dec; 6(6):631-633. PubMed ID: 27766597
    [No Abstract]   [Full Text] [Related]  

  • 17. Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept.
    Patel N; Thakkar V; Metalia V; Baldaniya L; Gandhi T; Gohel M
    Drug Dev Ind Pharm; 2016 Sep; 42(9):1406-23. PubMed ID: 26716613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular drugs and drug delivery systems - Current trends and future perspectives.
    Rupenthal ID; Daugherty AL
    Drug Discov Today; 2019 Aug; 24(8):1425-1426. PubMed ID: 31330186
    [No Abstract]   [Full Text] [Related]  

  • 19. Ocular preparations: the formulation approach.
    Kaur IP; Kanwar M
    Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained ocular delivery of Dorzolamide-HCl via proniosomal gel formulation: in-vitro characterization, statistical optimization, and in-vivo pharmacodynamic evaluation in rabbits.
    Fouda NH; Abdelrehim RT; Hegazy DA; Habib BA
    Drug Deliv; 2018 Nov; 25(1):1340-1349. PubMed ID: 29869516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.